RxSight (RXST – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Saxon from Needham reiterated a Buy rating on the stock and has a $22.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
David Saxon has given his Buy rating due to a combination of factors including RxSight’s recent financial performance and strategic developments. The company’s first quarter revenue for 2025 aligned with its earlier projections, which indicates stability and reliability in its financial forecasting. Additionally, RxSight has secured approval in South Korea and anticipates gaining approval in the UK in the second quarter of 2025, suggesting potential for international market expansion.
Furthermore, the company’s strong gross margin, bolstered by increased production efficiency of its LAL+ product, is expected to continue benefiting future quarters. The revenue outlook is optimistic for the latter half of 2025, as macroeconomic challenges are expected to diminish. Considering RxSight’s growth trajectory and current valuation, Saxon maintains a positive outlook, reinforcing the Buy recommendation.
Saxon covers the Healthcare sector, focusing on stocks such as RxSight, DENTSPLY SIRONA, and Staar Surgical. According to TipRanks, Saxon has an average return of -2.3% and a 34.03% success rate on recommended stocks.
In another report released yesterday, BTIG also maintained a Buy rating on the stock with a $28.00 price target.